{
  "id": "71fb3af65800ec3e",
  "title": "AbbVie Announces Topline Results for Epcoritamab ( DuoBody\u00ae CD3xCD20 ) from Phase 3 EPCORE\u00ae DLBCL - 1 Trial in Patients with Relapsed / Refractory Diffuse Large B - cell Lymphoma ( DLBCL ) ",
  "description": "20260116T191500Z",
  "content": "",
  "source": "prnewswire.com",
  "source_url": "https://www.prnewswire.com/news-releases/abbvie-announces-topline-results-for-epcoritamab-duobody-cd3xcd20-from-phase-3-epcore-dlbcl-1-trial-in-patients-with-relapsedrefractory-diffuse-large-b-cell-lymphoma-dlbcl-302663645.html",
  "published_at": "20260116T191500Z",
  "fetched_at": "2026-01-17T00:22:29.333379+00:00",
  "category": "health_biotech",
  "subcategory": null,
  "keywords": [],
  "location": "United States",
  "raw_data": {
    "url": "https://www.prnewswire.com/news-releases/abbvie-announces-topline-results-for-epcoritamab-duobody-cd3xcd20-from-phase-3-epcore-dlbcl-1-trial-in-patients-with-relapsedrefractory-diffuse-large-b-cell-lymphoma-dlbcl-302663645.html",
    "url_mobile": "",
    "title": "AbbVie Announces Topline Results for Epcoritamab ( DuoBody\u00ae CD3xCD20 ) from Phase 3 EPCORE\u00ae DLBCL - 1 Trial in Patients with Relapsed / Refractory Diffuse Large B - cell Lymphoma ( DLBCL ) ",
    "seendate": "20260116T191500Z",
    "socialimage": "",
    "domain": "prnewswire.com",
    "language": "English",
    "sourcecountry": "United States"
  }
}